|
Biomedical advances in the treatment of COVID-19: An Indo-Canadian perspective
Rohin K Iyer1, Venkat Venkataramanan2, Grant N Pierce3, Nikita Thakkar4, Valle Natarajan5, Arun Chockalingam6
1 Cytiva Life Sciences, Marlborough, MA, USA
2 McRae Imaging, Mississauga; Lumentra Inc., Waterloo, Ontario, Canada
3 Canadian Centre for Agri-Food Research in Health and Medicine, Albrechtsen Research Centre; St. Boniface Hospital, Department of Physiology and Pathophysiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
4 Department of LaboratoryMedicine and Pathobiology, University of Toronto, ON, Canada
5 Orchid Pharmaceuticals, Chennai, Tamil Nadu, India
6 Department of Medicine, University of Toronto, ON, Canada
Correspondence Address:
Nikita Thakkar
Department of LaboratoryMedicine and Pathobiology, University of Toronto, ON
Canada
Dr. Rohin K Iyer
Cytiva Life Sciences, Marlborough, MA
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2468-8827.330647
|
|
This white paper summarizes the key outcomes, topics, and recommendations from the Canada-India Healthcare Summit 2021 Conference, Biotechnology Session, held on May 20–21, 2021. In particular, the authors have focused their attention on topics ranging from research and development into the etiology and treatment of COVID-19 to novel approaches, such as ultraviolet-C disinfection and cell and gene therapy. The paper also deals with important topics around the effects of food distribution and nutrition on COVID-19 and vice versa, as well as key considerations around research and development, innovation, policy, grants, and incentives, and finally, summarizes the ways in which Canada and India, being close allies, have already begun to partner to fight the pandemic (as well as future strategies to continue this excellent progress). We also include key points raised during the summit and summarize them as part of this white paper.
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
